Breaking Finance News

MEI Pharma Inc (NASDAQ:MEIP) target price bumped up to $2.00, released a research note earlier today by Zacks Investment Research

Just yesterday MEI Pharma Inc (NASDAQ:MEIP) traded -1.14% lower at $1.73. MEI Pharma Inc’s 50-day moving average is $1.86 and its 200-day moving average is $1.49. The last closing price is up 16.01% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 376,065 shares of the stock traded hands, down from an avg. volume of 517,508

MEI Pharma Inc (NASDAQ:MEIP) had its target price raised to $2.00 by Zacks Investment Research in an issued report issued 9/23/2016. The upped target suggests a potential upside of 0.16% from the company's last stock price.

Recent Performance Chart

MEI Pharma Inc (NASDAQ:MEIP)

MEI Pharma Inc has 52 week low of $0.87 and a 52 week high of $2.28 and has a market capitalization of $0.

A total of 1 equity analyst has released a research note on MEIP. zero equity analysts rating the company a strong buy, zero firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $7.00.

General Information About MEI Pharma Inc (NASDAQ:MEIP)

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *